Loading company
Just reported
Q3 2026 results
From Emergent Biosolutions's results release of November 2, 2026; its quarterly report has since been filed.
Revenue
Actual
$110M
-52% y/y
-53% q/qGuided
$120M
midpoint
Within guide-8.3%EPS, GAAP
Actual
-$0.64
Guided
—
No guide given
Operating income, GAAP
Actual
-$37.3M
Guided
—
No guide given
Company outlook
Full year 2026
- Revenue$600M – $645M-16% y/y Lowered -5.7%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Emergent Biosolutions is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited$33.9BA
NBIXNeurocrine Biosciences, Inc.$17.2BA+
ELANElanco Animal Health Incorporated$13.3BA
KNSAKiniksa Pharmaceuticals International, plc$8.2BA+
LQDALiquidia Corporation$5.2BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now A
Built from Emergent Biosolutions Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
